ISRS delivers its 133rd Webinar
Since we launched our webinar program in Oct. 2016 we have delivered webinars on a fortnightly basis covering important topics related to intracranial and body SRS. These have become increasingly popular during the pandemic, attracting hundreds of registrants. We have now completed more than 120 webinars. This has been made possible due to the generosity of the speakers who have given their time to present high level lectures. Members can access recordings of all of the webinars via our website: Access the library here.
Upcoming Webinars
Evidence Review on Stereotactic Radiosurgery and Immunotherapy for Metastatic Brain Tumors / 転移性脳腫瘍に対する定位放射線治療とがん免疫療法に関するエビデンスレビュー
.jpeg)
Director of Gamma Knife Center, Division of Radiation Oncology, Aizawa Comprehensive Cancer Center, Aizawa Hospital, Nagano, Japan
June 20, 2023, 2pm CET
近年、免疫チェックポイント阻害剤の臨床応用により、様々な悪性腫瘍の進行がん患者の予後は大幅に改善されている。生存期間の延長に伴い、転移性脳腫瘍をいかにコントロールし、患者のQOLを維持するかがこれまで以上に重要となってきている。しかし、定位放射線治療と免疫チェックポイント阻害剤の併用が、どの程度予後を改善し、局所治療効果を高め、あるいは治療関連毒性を高めるのかについては、未だ十分に解明されていない。本レビューでは、最初に免疫チェックポイント阻害剤の分子メカニズムについて簡単に説明する。次に免疫チェックポイント阻害剤の臨床試験から得られた現在入手可能なエビデンスを要約する。最後に脳転移に対する定位放射線治療と免疫チェックポイント阻害剤の併用療法に関する臨床データを我々の経験からのデータも含めて紹介する。
The recent clinical application of immune checkpoint inhibitors has substantially improved the prognosis of advanced cancer patients in various malignancies. With prolonged survival, how to control metastatic brain tumors and maintain the quality of a patient's life has become more important than ever before. However, the extent to which the combination of stereotactic radiotherapy with immune checkpoint inhibitors improves prognosis, enhances local therapeutic efficacy, or increases treatment-related toxicity remains to be fully elucidated. In this review, we first provide a brief overview of the molecular mechanisms of immune checkpoint inhibitors. Next, currently available evidence from clinical trials of immune checkpoint inhibitors will be summarized. Finally, we will present clinical data on the combination of stereotactic radiotherapy and immune checkpoint inhibitors for brain metastases, including data from our experience.
REGISTER